Biomarker conservation in primary and metastatic epithelial ovarian cancer

被引:45
作者
Tewari, KS
Kyshtoobayeva, AS
Mehta, RS
Yu, IR
Burger, RA
DiSaia, PJ
Fruehauf, JP
机构
[1] Oncotech Inc, Irvine, CA 92614 USA
[2] Univ Calif Irvine, Irvine Med Ctr, Chao Family Comprehens Canc Ctr, Div Gynecol Oncol,Sect Hematol & Oncol, Orange, CA 92868 USA
关键词
ovarian cancer; biomarkers; biologic prognostic factors; clonal divergence; angiogenesis; tumor heterogeneity;
D O I
10.1006/gyno.2000.5837
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. The aim of this study was to compare the overexpression of specific biomarkers in primary advanced and recurrent epithelial ovarian cancers. Methods. Biomarker expression by epithelial ovarian cancer specimens from primary and metastatic sites was examined by immunohistochemistry and flow cytometry. Biomarker expression by subpopulations of tissues consisting of matched pairs of synchronous and metachronous lesions was also studied. Results. A total of 3173 epithelial ovarian cancer specimens were retrieved from women with FIGO Stage III/IV disease. These included lesions from 1036 primary and 2137 metastatic sites. The percentages of biomarker expression for primary and metastatic lesions, respectively, were MDR1, 12 and 10%; p53, 55 and 60%; HER2, 12 and 11%; EGF-R, 26 and 33%; increased microvessel counts (CD31), 21 and 36%. Approximately 73% of both primary and metastatic specimens were aneuploid, and approximately 57% of both sets had an S-phase fraction >7%. Only EGF-R and CD31 expression were found to be significantly different between the primary and metastatic tumors (P < 0.05). Of the paired synchronous cases (n = 48) evaluated, 88% of aneuploid primary lesions were associated with aneuploid metastases. Similarly, the distributions for MDR1, HER2, and p53 expression did not vary significantly between primary and metastatic sites. Pairings of metachronous cases (n = 66) revealed that nearly 80% of primary aneuploid tumors (n = 39) retained their aneuploid status at the time of relapse. Furthermore, there were no significant changes in MDR1, p53, or HER2 expression at relapse. Conclusions. With the exception of EGFR and CD31, clonal divergence of the biomarkers evaluated in this study probably does not play a significant role in imparting clinical heterogeneity during the advanced and recurrent stages of epithelial ovarian cancer. These particular genes likely undergo alterations early in the tumorigenesis process before metastases have become established, (C) 2000 Academic Press.
引用
收藏
页码:130 / 136
页数:7
相关论文
共 32 条
[1]   MOLECULAR-GENETIC EVIDENCE FOR UNIFOCAL ORIGIN OF ADVANCED EPITHELIAL OVARIAN-CANCER AND FOR MINOR CLONAL DIVERGENCE [J].
ABELN, ECA ;
KUIPERSDIJKSHOORN, NJ ;
BERNS, EMJJ ;
HENZENLOGMANS, SC ;
FLEUREN, GJ ;
CORNELISSE, CJ .
BRITISH JOURNAL OF CANCER, 1995, 72 (05) :1330-1336
[2]  
BOVERI T, 1914, FRAGE ERSTEHUNG MALI
[3]  
Brinkhuis M, 1997, ANAL QUANT CYTOL, V19, P185
[4]   Detection of cellular heterogeneity by DNA ploidy, 17 chromosome, and p53 gene in primary carcinoma and metastasis in a case of ovarian cancer [J].
Calugi, A ;
Eleuteri, P ;
Cavallo, D ;
Naso, G ;
Albonici, L ;
Lombardi, MP ;
Manzari, V ;
Romanini, C ;
DeVita, R .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1996, 15 (01) :77-81
[5]   p53 expression, DNA content and cell proliferation in primary and synchronous metastatic lesions from ovarian surface epithelial-stromal tumours [J].
Daidone, MG ;
Benini, E ;
Valentinis, B ;
Bolis, G ;
Villa, A ;
Silvestrini, R .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (08) :1388-1393
[6]  
DEMBO AJ, 1987, J REPROD MED, V32, P669
[7]  
Friedlander ML, 1998, SEMIN ONCOL, V25, P305
[8]  
GALLION HH, 1995, CANCER, V76, P1992, DOI 10.1002/1097-0142(19951115)76:10+<1992::AID-CNCR2820761315>3.0.CO
[9]  
2-U
[10]  
Gasparini G, 1996, INT J CANCER, V69, P205, DOI 10.1002/(SICI)1097-0215(19960621)69:3<205::AID-IJC10>3.0.CO